CVM - cel-sci.com Long-Term Debt

CEL-SCI Corporation (CVM) is a biotech company developing Multikine immunotherapy to combat head and neck tumors, with prospects contingent upon the FDA verdict and the launch of its own production facilities. The company will generate revenue through the sale of this drug during pre-operative stages. This chart of the company's market valuation on GURU.Markets, where the indicator stands at 0.01, confirms business resilience driven by the ownership of exclusive patents for the platform.

Long-term debt defines the volume of obligations with a maturity exceeding one year, allowing for an assessment of the liability structure's stability and interest expense risks during an economic slowdown. By analyzing the history of the organization's long-term financial debt, an investor can identify the resource base for capital-intensive projects, which is critically important for CEL-SCI Corporation (CVM) when implementing multi-year clinical trials in the field of cancer immunotherapy.